Literature DB >> 18339018

Erythromycin attenuates MUC5AC synthesis and secretion in cultured human tracheal cells infected with RV14.

Daisuke Inoue1, Hiroshi Kubo, Takahiko Sasaki, Hiroyasu Yasuda, Muneo Numasaki, Hidetada Sasaki, Mutsuo Yamaya.   

Abstract

BACKGROUND AND
OBJECTIVE: The common cold is a major cause of asthma exacerbation and chronic obstructive lung disease. Rhinovirus is reported to be responsible for more than 50% of cases of the common cold. In a previous study, we reported that rhinovirus infection of cultured airway cells induced MUC5AC mucin overproduction and hypersecretion by activating the p44/42 mitogen-activated protein kinase (p44/42 MAPK) pathway. The aim of this study was to examine the effect of erythromycin on RV14-induced airway mucin overproduction and hypersecretion.
METHODS: RV14-infected human tracheal epithelial cells were treated with erythromycin.
RESULTS: Erythromycin blocked RV14-induced MUC5AC protein overproduction and hypersecretion, and also blocked RV14-induced p44/42 MAPK activation in the cells.
CONCLUSIONS: Erythromycin may attenuate RV14-induced MUC5AC overproduction and hypersecretion by blocking the p44/42 MAPK pathway or its upstream regulators.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18339018     DOI: 10.1111/j.1440-1843.2007.01227.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  5 in total

Review 1.  Targeting mucus hypersecretion: new therapeutic opportunities for COPD?

Authors:  Clémence Martin; Justine Frija-Masson; Pierre-Régis Burgel
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

Review 2.  Macrolide therapy in respiratory viral infections.

Authors:  Jin-Young Min; Yong Ju Jang
Journal:  Mediators Inflamm       Date:  2012-06-06       Impact factor: 4.711

3.  Potential Role of Nrf2 Activators with Dual Antiviral and Anti-Inflammatory Properties in the Management of Viral Pneumonia.

Authors:  Chih-Yin Lin; Chun-An Yao
Journal:  Infect Drug Resist       Date:  2020-06-11       Impact factor: 4.003

Review 4.  Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.

Authors:  Leena Abdulaziz; Esraa Elhadi; Ejlal A Abdallah; Fadlalbaseer A Alnoor; Bashir A Yousef
Journal:  J Exp Pharmacol       Date:  2022-03-08

5.  Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum.

Authors:  David J Serisier; Mary P Carroll; Janis K Shute; Simon A Young
Journal:  Respir Res       Date:  2009-07-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.